- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biodexa Pharmaceuticals PLC DRC (BDRX)
Biodexa Pharmaceuticals PLC DRC stock price live, this page displays NASDAQ BDRX stock exchange data. View the BDRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Biodexa Pharmaceuticals PLC DRC real time stock price chart below.
What Is the Biodexa Pharmaceuticals PLC DRC Stock Price Today?
The Biodexa Pharmaceuticals PLC DRC stock price today is 6.760.
What Is the Stock Symbol for Biodexa Pharmaceuticals PLC DRC?
The stock symbol for Biodexa Pharmaceuticals PLC DRC is ""BDRX.""
What Stock Exchange Does Biodexa Pharmaceuticals PLC DRC Trade On?
Biodexa Pharmaceuticals PLC DRC is listed and trades on the NASDAQ stock exchange.
Is Biodexa Pharmaceuticals PLC DRC a Good Stock to Buy?
Determining whether Biodexa Pharmaceuticals PLC DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BDRX quote. (ISIN: US59564R8806)
What Is the Biodexa Pharmaceuticals PLC DRC Stock Price Today?
The Biodexa Pharmaceuticals PLC DRC stock price today is 6.760.
What Is the Stock Symbol for Biodexa Pharmaceuticals PLC DRC?
The stock symbol for Biodexa Pharmaceuticals PLC DRC is ""BDRX.""
What Stock Exchange Does Biodexa Pharmaceuticals PLC DRC Trade On?
Biodexa Pharmaceuticals PLC DRC is listed and trades on the NASDAQ stock exchange.
Is Biodexa Pharmaceuticals PLC DRC a Good Stock to Buy?
Determining whether Biodexa Pharmaceuticals PLC DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BDRX quote. (ISIN: US59564R8806)
NASDAQ
Currency in USD
6.760
-0.220(-3.15%)
Closed·
After Hours
6.650-0.110(-1.63%)
·
Fair Value
An estimate of a Biodexa Pharmaceuticals DRC's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.635
7.200
52 wk Range
5.852
163.100
BDRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
BDRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Biodexa Pharmaceuticals DRC's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.6357.200
52 wk Range
5.852163.100
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BDRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Biodexa Pharmaceuticals DRC's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
181.200
Upside
+2,580.47%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 6K Biodexa Pharmaceuticals PLC DRC For: 27 June
- Investing.com
- Results of Annual General Meeting
- Investing.com
- Form 6K Biodexa Pharmaceuticals PLC DRC For: 15 July
- Investing.com
- Form 6K Biodexa Pharmaceuticals PLC DRC For: 15 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Biodexa Pharmaceuticals PLC DRC Company Profile
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Compare BDRX to Peers and Sector
Metrics to compare | BDRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBDRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | −6.8x | −0.5x | |
PEG Ratio | - | 0.24 | 0.00 | |
Price/Book | 0.4x | 5.4x | 2.6x | |
Price / LTM Sales | - | 37.8x | 3.3x | |
Upside (Analyst Target) | - | 96.5% | 43.5% | |
Fair Value Upside | Unlock | −21.5% | 6.9% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 181.200
(+2,580.47% Upside)
Earnings
Latest Release
Apr 11, 2025
EPS / Forecast
-18.27 / --
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Biodexa Pharmaceuticals DRC Trade On?
Biodexa Pharmaceuticals DRC is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Biodexa Pharmaceuticals DRC?
The stock symbol for Biodexa Pharmaceuticals DRC is "BDRX."
What Is the Biodexa Pharmaceuticals DRC Market Cap?
As of today, Biodexa Pharmaceuticals DRC market cap is 4.32M.
What Is Biodexa Pharmaceuticals DRC's Earnings Per Share (TTM)?
The Biodexa Pharmaceuticals DRC EPS (TTM) is -115.67.
From a Technical Analysis Perspective, Is BDRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Biodexa Pharmaceuticals DRC Stock Split?
Biodexa Pharmaceuticals DRC has split 7 times.
How Many Employees Does Biodexa Pharmaceuticals DRC Have?
Biodexa Pharmaceuticals DRC has 13 employees.
What is the current trading status of Biodexa Pharmaceuticals DRC (BDRX)?
As of 07 Aug 2025, Biodexa Pharmaceuticals DRC (BDRX) is trading at a price of 6.76, with a previous close of 6.98. The stock has fluctuated within a day range of 6.64 to 7.20, while its 52-week range spans from 5.85 to 163.10.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.